Tiziana Life Sciences plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Tiziana Life Sciences plc
Lilly hopes to address immunology and pain indications with biotech’s LYTAC technology. Sunovion licenses European rights to Parkinson’s therapy Kynmobi to Bial.
In search of a differentiated approach, candidate aims to boostT-cell immune responses via a subcutaneous and oral vaccine combination.
Altimmune’s hopes of bringing a nasal COVID-19 vaccine to market have been dashed, but it is pivoting to novel peptide-based therapies.
A COVID-19 vaccine in a pill being developed by Vaxart and a nasal spray from Altimmune could offer convenience and maybe even superior immunity compared to injections.
- Large Molecule
- Other Names / Subsidiaries
- LonGevia Genomics Srl
- Shardna SpA
- Tiziana Group
- Tiziana Life Sciences Ltd.